• H1 FY26 revenue up 44% to $25.5M, Underlying EBITDA up 675% to $4.2M
• ARR as at 31 Dec 2025 up 9.1% to $31.1M, FY26 contracted revenue up 40% to $43.1M
• Selected as preferred supplier for University Hospitals Sussex NHS Foundation Trust EPR solution

Alcidion Group Limited (ASX:ALC) has released its financial results for the six months ending 31 December 2025 (H1 FY26), highlighting accelerating revenue growth and improved profitability. The company reported H1 FY26 revenue of $25.5M, up 44% on the prior corresponding period, and an Underlying EBITDA of $4.2M, an improvement of $3.7M (+675%) compared to the same period last year. Annual Recurring Revenue (ARR) as at 31 December 2025 was $31.1M, up 9.1% from 30 June 2025. As of 31 December 2025, Alcidion had contracted (sold and renewal) revenue for FY26 of $43.1M, up 40% on the prior corresponding period. The company was also selected as the preferred supplier by University Hospitals Sussex NHS Foundation Trust (UHSussex) for its new Electronic Patient Record (EPR) solution, with an estimated total contract value of at least $35M. Alcidion CEO Kate Quirke said the results demonstrate the company's momentum and the value of its increasing customer base. The company is reconfirming its FY26 guidance of revenue exceeding $50M with EBITDA in excess of $5M, and positive operating cashflow in-line with FY25. Alcidion is continuing to pursue its growth strategy, including scaling in existing markets, evolving product functionality, geographic expansion, and assessing potential M&A opportunities.

Revenue expected to exceed $50.0M with EBITDA in excess of $5.0M for FY26.

Alcidion is continuing to pursue its growth strategy across several key pillars, including scaling in existing markets, evolving product functionality and market adjacencies, geographical expansion, and assessing potential M&A opportunities.